



COMPOSITE PERFORMANCE (% TOTAL RETURN) FOR PERIODS ENDED JUNE 30, 2020¹

	3 MONTHS	YTD	1 YEAR	3 YEARS ²	5 YEARS ²	10 YEARS ²	SINCE INCEPTION ^{2,3}
HL INTL SMALL COMPANIES (GROSS OF FEES)	24.66	-7.96	1.06	4.43	6.74	10.36	8.08
HL INTL SMALL COMPANIES (NET OF FEES)	24.32	-8.48	-0.09	3.29	5.59	9.16	6.89
MSCI ALL COUNTRY WORLD EX-US SMALL CAP INDEX ^{4,5}	22.98	-12.61	-3.99	0.20	2.88	6.42	3.57

¹The Composite performance returns shown are preliminary; ²Annualized Returns; ³Inception Date: December 31, 2006; ⁴The Benchmark Index; ⁵Gross of withholding taxes.

Please read the above performance in conjunction with the footnotes on the back page of this report. Past performance does not guarantee future results. All performance and data shown are in US dollar terms, unless otherwise noted.

SECTOR EXPOSURE (%)

GEOGRAPHIC EXPOSURE (%)


⁶Includes countries with less-developed markets outside the Index; ⁷Includes companies classified in countries outside the index.

Sector and geographic allocations are supplemental information only and complement the fully compliant International Small Companies Composite GIPS Presentation.

Source: Harding Loevner International Small Companies Model; MSCI Inc. and S&P MSCI Inc. and S&P do not make any express or implied warranties or representations and shall have no liability whatsoever with respect to any GICS data contained herein.

WHAT'S INSIDE
Market Review >

Stocks of international small companies rebounded sharply from the first quarter COVID-19 selloff, as countries started reopening and monetary support boosted riskier assets.

Performance and Attribution >

Sources of relative return by region and sector.

Perspective and Outlook >

As the coronavirus emerges as a potential tipping point for research funding, it may also represent an inflection in the health care investment landscape.

Portfolio Highlights >

Prices again influenced many of our changes as companies grew either too large or too expensive relative to growth prospects to justify continue holding.

Portfolio Holdings >


Information about the companies held in our portfolio, and completed transactions.

Portfolio Facts >

Contributors, detractors, and characteristics.

ONLINE SUPPLEMENTS

 Watch the Intl Small Companies Equity quarterly review

 View other reports at hardingloevner.com/library

MARKET REVIEW

Stocks of international small companies returned 23%, rebounding sharply from the first quarter COVID-19 related selloff, as countries around the world started to reopen. Small caps outperformed large caps, in part due to the ongoing monetary support from central banks that is helping to boost prices of riskier assets.

While business activity remained weak, economic data signaled a nascent recovery. Several indicators, including unemployment, consumer spending, and service and manufacturing surveys, reflected notable improvements from trough levels seen in April. Progress toward a vaccine also boosted sentiment, despite rising cases of the novel coronavirus in many countries including the United States and much of Latin America.

To help hard-hit economies, governments and central bankers provided extraordinary fiscal and monetary support. Governments in aggregate introduced an additional \$3 trillion in fiscal stimulus during the quarter to combat weak economic conditions, bringing the total since the outbreak to about \$11 trillion, according to the International Monetary Fund. The US, Japan, and Europe boosted direct cash transfers to citizens and China dusted off its battle-tested financial-crisis playbook, funneling funds to local governments for infrastructure spending. Global governmental debt as a percentage of global GDP is now expected to surpass 100% for the first time ever. Central bankers also remained highly accommodative across the world, with short-term interest rates hovering near-zero in every major economy, and guidance for more of the same for many months to come.

Currency effects in the quarter showed a nearly uniform reversal of the flight to safe-haven currencies. With the exception of the Hong Kong dollar, every major currency managed some appreciation against the US dollar, though currencies of many commodity-exporting countries remained down significantly for the year. The British pound also stayed negative year-to-date as investors refocused on stalled Brexit negotiations.

Consumer Discretionary and Materials, both hard hit in the first quarter, were among the best-performing sectors as modest improvement in economic activity boosted sentiment and commodity prices. Information Technology (IT) and Health Care, two sectors that outperformed last quarter, continued their run. Increased adoption of cloud-based applications and rising levels of investment in next-generation mobile technology extended demand for semiconductors, hardware, and software-as-a-service (SaaS) companies. Health Care performance was largely driven by pharmaceutical and life sciences companies engaged in trying to find effective treatments for COVID-19. Real Estate was the worst-performing sector due to prospects for rising vacancies in commercial buildings.

Returns by geography were broadly positive. Countries reliant on the sale of commodities, such as Canada, Russia, and Brazil, were among the best-performing this quarter. Japan was the notable underperformer, with several factors contributing: a rise in coronavirus cases (from a low base); a cumbersome application

MARKET PERFORMANCE (USD %)

MARKET	2Q 2020	TRAILING 12 MONTHS
CANADA	44.3	1.2
EMERGING MARKETS	27.3	-8.1
EUROPE EMU	22.9	-5.6
EUROPE EX-EMU	21.1	-5.0
JAPAN	12.8	1.5
MIDDLE EAST	5.6	-8.3
PACIFIC EX-JAPAN	35.7	-5.7
MSCI ACW EX-US SC INDEX	23.0	-4.0

SECTOR PERFORMANCE (USD %) OF THE MSCI ACW EX-US SMALL CAP INDEX

SECTOR	2Q 2020	TRAILING 12 MONTHS
COMMUNICATION SERVICES	21.3	-4.8
CONSUMER DISCRETIONARY	27.3	-10.0
CONSUMER STAPLES	15.5	1.6
ENERGY	21.2	-42.5
FINANCIALS	18.0	-14.8
HEALTH CARE	23.8	15.9
INDUSTRIALS	22.6	-8.5
INFORMATION TECHNOLOGY	33.4	18.8
MATERIALS	34.7	1.7
REAL ESTATE	10.8	-10.1
UTILITIES	18.7	2.0

Source: FactSet (as of June 30, 2020); MSCI Inc. and S&P.

process that slowed stimulus funds reaching small businesses; and a slowing rate of equity purchases by the Bank of Japan.

In terms of style, growth, quality, and valuation factor, effects were all generally in our favor this quarter. Of the three, growth was the most pronounced, as the fastest-growing quintile of the index outperformed the slowest by nearly 2000 bps. The effects of quality were mixed: while high-quality growth companies continued to outperform, there was a sharp recovery in many lower-quality companies in beaten-up cyclical sectors.

PERFORMANCE AND ATTRIBUTION

The International Small Companies composite rose 25% in the quarter, outpacing the 23% gain of the index.

By sector, our longstanding overweight to IT again positively contributed to our relative performance. Shares of **Kinaxis**, a Canadian-based provider of supply-chain management software, continued to outperform as companies assess global supply chain resilience in the face of COVID-19 disruptions. Taiwan-based **Silergy**, a semiconductor equipment company that designs and sells power management integrated circuits, also outperformed, driven primarily by its 5G cellular and industrials markets.

Poor stock selection within Health Care partially offset gains in IT. We missed out on a handful of outperforming biotechnology stocks in the index, and some of our Health Care equipment holdings underperformed. One culprit was Japanese-based **Nakanishi**, a global seller of dental handpieces. The company has struggled to grow in the US over the past few years and, near-term, it faces high marketing and distribution costs to expand its presence in China. Another detractor was Germany's **Carl Zeiss**, a maker of ophthalmic equipment and microscopes. Much of its revenue is tied to elective surgeries and hospital capital expenditure, which have declined sharply during the pandemic.


By region, Japan was the largest contributor to relative returns due to the combined effect of good selection and our underweight. Japan-based **Nihon M&A Center**, an advisor to other small companies on mergers and acquisitions, was an especially successful stock. Between a secular trend of aging demographics and near-term uncertainty around the pandemic, there has been a rise in Japanese businesses pursuing succession plans, Nihon's specialty. Indeed, the firm is hiring more salespeople to ensure it captures the growth. Shares of **MonotaRO**, a distributor of maintenance, repair, and operations goods to small and medium-sized enterprises, surged in the quarter as the company reported 19% sales growth along with margin improvement. Strong new customer growth is getting a boost from companies looking to retool and repair existing equipment and operations instead of springing for major new capital expenditures. Beyond Japan, though, our underweight to the rest of the Pacific region, particularly Australia, detracted from our relative returns.

PERSPECTIVE AND OUTLOOK


Prior to the current pandemic, the scientific community essentially had two chances to develop a successful coronavirus vaccine or treatment, first with SARS in 2002-2004 and then with MERS starting in 2012. Given their similarities to SARS-CoV2, substantial progress on either virus would have put scientists in a better position to respond to the coronavirus outbreak that started in Wuhan China in December. Because the spread of those diseases was limited, however, pharmaceutical companies eventually shifted their focus to more profitable illnesses. The question now is whether the tragic example of SARS-CoV2 will be the tipping point that brings about a sustained commitment to viral vaccine and treatment development. Early indications are that it will. It was notable, for example, that when the US Congress recently awarded the National Institutes of Health (NIH) \$3.6 billion in additional COVID-19 research funding, it gave NIH five years to disburse the funds, a marked departure from the months-long timeframes associated with past emergency

Companies held in the portfolio during the quarter appear in bold type; only the first reference to a particular holding appears in bold. The portfolio is actively managed therefore holdings shown may not be current. Portfolio holdings should not be considered recommendations to buy or sell any security. It should not be assumed that investment in the security identified has been or will be profitable. To request a complete list of holdings for the past year, please contact Harding Loevner. A complete list of holdings at June 30, 2020 is available on page 6 of this report.

SECTOR PERFORMANCE ATTRIBUTION SECOND QUARTER 2020



GEOGRAPHIC PERFORMANCE ATTRIBUTION SECOND QUARTER 2020



¹Includes countries with less-developed markets outside the Index; ²Includes companies classified in countries outside the index. Source: FactSet; Harding Loevner International Small Companies Composite; MSCI Inc. and S&P. The total effect shown here may differ from the variance of the Composite performance and benchmark performance shown on the first page of this report due to the way in which FactSet calculates performance attribution. This information is supplemental to the Composite GIPS Presentation.

infusions. The German government has likewise begun investing in its pharmaceutical companies, and numerous other agencies around the world have signaled increased levels of commitment. Thus, the pandemic may also represent an inflection in the health care investment landscape.

How this plays out for the smaller pharmaceutical and equipment makers ultimately will have a lot to do with industry structure. The smaller companies ordinarily avoid competing for funding or market share with the big pharmaceutical and diagnostic firms, whose economies of scale in R&D, marketing, and manufacturing allow them to dominate the sector. Instead, they focus on niche products too small to interest the large players, or on developing specific technologies applicable to drug discovery, testing, or treatment that are useful to the large players—like monoclonal

antibodies, a highly sought-after class of lab-cultured proteins that are the purview of UK-based [Abcam](#).

In the immune system's millennia-long war of attrition with the (now-) 219 known human viruses, antibodies are the original frontline workers. After a person inhales SARS-CoV2 particles, spike-shaped proteins on the outer casing of the virus bind with a receptor on cells lining the airways and lungs. Once attached, the virus enters the cell and co-opts the cell's machinery to pump out copies of itself to infect more cells. Antibodies are free-floating proteins in the bloodstream charged with detecting and turning back these attacks, either by interrupting the binding process or by latching onto the virus and thereby marking it for destruction by other defensive proteins dispatched to the scene by the immune system. When a virus is new, like SARS-CoV2, the immune system is often slow to recognize the threat or figure out how to respond. Most COVID-19 treatments now under investigation represent attempts to compensate for that lag by speeding up the immune system's learning curve.

Abcam is in the business of cataloguing and manufacturing proteins, including antibodies. The company offers for sale on a user-friendly e-commerce platform over 120,000 different research-grade proteins. Researchers in all aspects of the race for a COVID-19 cure depend on the site's validation of listings' research potential and fellow users' ratings and comments on proteins' binding properties and other relevant factors.

Still, as much as these products have been in demand recently, infectious disease research represents just one of the company's important markets. In the past decade the immune system's role in many other types of serious disease has become a hot research topic, and each of a large number of major medical specialties has its own extensive catalogue on Abcam's site. As a result, the net impact of the coronavirus on near-term growth has been mixed as COVID-19-related closures of research labs worldwide have cut into Abcam's sales of reagents used in cancer immunotherapy, neuroscience, and cardiology, among others. We think this headwind is temporary. Prior to the pandemic, Abcam projected its addressable market would grow 4% to nearly \$3 billion by 2022. With other research areas starting to come back online, and the higher levels of funding for primary immunology research we expect, those estimates look conservative to us now.

Another important aspect in fighting a virus, of course, involves mass testing to identify those in need of treatment and to help contain outbreaks. Equipment makers and suppliers of automation and instrumentation technology, such as German-based [Stratec Biomedical](#), are critical in this endeavor. Stratec provides equipment and services to larger diagnostic equipment companies such as Siemens, Immucor, and Dialogic, which then provide the final product to medical diagnostic labs such as Quest Diagnostics.

Stratec is typically paid by its clients as it hits certain developmental milestones, such as producing a functional prototype, or earning FDA approval. Once the development

is finished, Stratec earns additional revenue for each analyzer produced for the diagnostic company. Substantial profits come only after Stratec is producing the analyzer at scale. Several of Stratec's projects in which it has invested heavily are just now entering full production. These include FACSDuet, an automated fluid- and tissue-sample preparation system developed for Becton Dickinson; and Simoa Disc, a high-sensitivity, low-cost array system for Quanterix's testing equipment. Both should see rapid adoption as labs straining under COVID-19 demand desperately seek to improve efficiency and accuracy across their operations.

In the US, 45% of the independent testing market is controlled by two companies: Quest Diagnostics and Lab Corp of America. Outside the US, two small cap companies in our portfolio have similarly dominant positions in their respective markets. These are [BML Inc.](#), based in Japan, and [Integrated Diagnostic Holdings](#) (IDHC), in Egypt. With over 1,600 points of collection and distribution and a fully automated central processing facility, BML is the clear leader in high-volume testing in Japan. As with Abcam, revenues have weakened in the near term. Japan's COVID-19 infection rate, while having risen recently, is still well below those of most other developed countries. This has meant limited virus testing demand to offset a fall-off in non-urgent bloodwork during the pandemic. On a multi-year view, however, the company remains well positioned for growth in a market with an aging population and rates of diagnostic testing that have historically been among the highest in the developed world.

IDHC is Egypt's largest private diagnostic lab testing company, with over 400 collection centers, giving it the scale to source reagents at lower prices than its competitors and attract a corporate government as well as retail clientele. To date, all COVID-19 testing in Egypt has been performed by state-run labs, but IDHC has been gearing up for a potential handoff. It has also been resourceful in expanding house calls for routine sample collection to make up for reduced traffic to its physical locations. With Egypt having one of the world's lowest levels of diagnostic tests per capita—but also among the highest incidences of lifestyle diseases such as obesity, diabetes, and hypertension—the company has a long runway for potential growth.

■ PORTFOLIO HIGHLIGHTS

In recent letters, we have bemoaned the expensive valuations for the highest-quality and fastest-growing companies and highlighted our ongoing challenge in balancing our commitment to maintaining a portfolio of quality-growth small cap companies with our insistence on owning them at a reasonable price. Unsurprisingly, many of our portfolio changes this quarter were again influenced by prices.

We sold three companies that had grown too large to remain in our small cap portfolio. Italian-based diagnostic company [DiaSorin](#) was the most extreme example. Its shares have performed very well on a relative basis as the company has

been inundated with demand for COVID-19 testing in a country that saw heartbreaking levels of illness earlier this spring. While the company continues to meet our quality and growth criteria, at a now-\$10 billion market cap, it has simply outgrown the portfolio. **Alfa Laval**, a Swedish manufacturer of heat exchangers, and **MonotaRo**, a Japanese wholesaler of maintenance, repair, and operations supplies, were the other two size-driven sales in the quarter.

We also sold French-based textile producer **Chargeurs**, another company that is experiencing increased orders due to the pandemic. After adroitly adapting its production in March, the company has seen impressive growth in its new lines of masks, gowns, and sanitizing gel. We think its shares fairly reflect this pivot, but not necessarily the ongoing challenges to its core fashion textiles and protective films businesses.

Our sales of **Danieli** and **Findex** were also the result of a deterioration in growth prospects. While **Danieli**, an Italian-based specialty steel company, has accumulated a solid backlog of orders for its digital transformers—used in powering electric arc furnaces—growing competition and weaker demand for its other products have dampened potential growth. **Findex**, based in Japan, has perhaps similarly limited future potential for its medical database management systems given the stiff competition for new products beyond its core imaging management systems.

Proceeds from these sales and other trims were directed towards more attractively priced companies, including additions to **Stratec**, Dubai-headquartered payments company **Network International**, UK-Healthcare software and services provider **EMIS**, and two Mexican holdings, **Megacable**, and the staples company **Grupo Herdez**.

We also added two new positions this quarter. Japanese-based **JCU** is a specialty chemicals company that provides surface plat-

ing solutions, with a focus on the copper plating additives used in smartphone printed circuit boards (PCBs). We expect demand for these additives to increase as 5G is adopted globally. The company has ~60% market share in a niche that represents a small percentage of the overall materials bill for its customers, giving it the inside track on a high-value, low-price product in a growing market.

The other new holding was Finland-based tire manufacturer **Nokian Tyres**. The effect of the pandemic on auto demand has been severe, but the company has a strong balance sheet. We also think tire demand, particularly in Nokian's focus areas of the replacement market like snow and industrial tires, will recover over time. The recent weakness in its shares provided an attractive entry point. The company recently announced the hiring of its newly elected CEO, **Jukka Moisio**, a highly regarded executive with a good track record of improving growth as CEO of Finnish food packager **Huhtamaki**.



Management Update

At the end of this year, as the natural next step in a long-planned succession, **Ferrill Roll, CFA**, who has shared Chief Investment Officer responsibilities with **Simon Hallett, CFA** since 2016, will become sole CIO. Simon will continue to contribute actively to **Harding Loevner** and our clients by engaging in the thought leadership activities he relishes, exploring and educating internal and external audiences on vital investment questions. He will remain a partner of **Harding Loevner** and continue to advise us on strategic matters as vice chairman of the firm's Executive Committee.

PORTFOLIO CHARACTERISTICS

QUALITY & GROWTH	HL ISC	ACWI EX-US SC
PROFIT MARGIN ¹ (%)	11.0	7.0
RETURN ON ASSETS ¹ (%)	9.0	5.0
RETURN ON EQUITY ¹ (%)	14.9	9.9
DEBT/EQUITY RATIO ¹ (%)	26.0	53.2
STD DEV OF 5 YEAR ROE ¹ (%)	3.3	4.1
SALES GROWTH ^{1,2} (%)	6.1	3.8
EARNINGS GROWTH ^{1,2} (%)	8.4	7.8
CASH FLOW GROWTH ^{1,2} (%)	11.0	8.7
DIVIDEND GROWTH ^{1,2} (%)	8.0	6.1
SIZE & TURNOVER	HL ISC	ACWI EX-US SC
WTD MEDIAN MKT CAP (US \$B)	2.5	1.7
WTD AVG MKT CAP (US \$B)	3.0	2.1
TURNOVER ³ (ANNUAL %)	26.0	—

RISK AND VALUATION	HL ISC	ACWI EX-US SC
ALPHA ² (%)	3.94	—
BETA ²	0.94	—
R-SQUARED ²	0.92	—
ACTIVE SHARE ³ (%)	97	—
STANDARD DEVIATION ² (%)	16.26	16.56
SHARPE RATIO ²	0.34	0.10
TRACKING ERROR ² (%)	4.6	—
INFORMATION RATIO ²	0.83	—
UP/DOWN CAPTURE ²	105/89	—
PRICE/EARNINGS ⁴	24.7	14.0
PRICE/CASH FLOW ⁴	15.3	8.0
PRICE/BOOK ⁴	3.0	1.2
DIVIDEND YIELD ⁵ (%)	1.8	2.9

¹Weighted median; ²Trailing five years, annualized; ³Five-year average; ⁴Weighted harmonic mean; ⁵Weighted mean. Source (Risk characteristics): eVestment Alliance (eA); **Harding Loevner International Small Companies Composite**, based on the Composite returns; MSCI Inc. Source (other characteristics): FactSet (Run Date: July 5, 2020 based on the latest available data in FactSet on this date.); **Harding Loevner International Small Companies Model**, based on the underlying holdings; MSCI Inc.

Portfolio characteristics are supplemental information only and complement the fully compliant **International Small Companies Composite GIPS Presentation**.

INTERNATIONAL SMALL COMPANIES HOLDINGS (AS OF JUNE 30, 2020)

SECTOR/COMPANY/DESCRIPTION	COUNTRY	END WT (%)
COMMUNICATION SERVICES		
CHEIL WORLDWIDE Marketing and advertising services	South Korea	0.2
MEGACABLE Cable operator	Mexico	1.0
PARADOX INTERACTIVE Video game publisher	Sweden	2.1
PICO FAR EAST HOLDINGS Event marketing services	Hong Kong	0.1
RIGHTMOVE OnLine property listings operator	UK	0.9
SARANA MENARA NUSANTARA Telecom infrastructure provider	Indonesia	1.4
TIME DOTCOMBERHAD Telecom services	Malaysia	0.7
TOWER BERSAMA Telecom infrastructure provider	Indonesia	1.2
YOUGOV Market research and data analytics services	UK	1.3
CONSUMER DISCRETIONARY		
ABC-MART Footwear retailer	Japan	0.4
ECLAT TEXTILE Technology-based textile manufacturer	Taiwan	0.5
JARIR MARKETING Consumer products retailer	Saudi Arabia	1.0
NOKIAN TYRES Tire manufacturer	Finland	0.5
RINNAI Consumer appliances manufacturer	Japan	0.3
STANLEY ELECTRIC Automotive lighting manufacturer	Japan	1.8
THULE GROUP Transportation equipment manufacturer	Sweden	0.4
CONSUMER STAPLES		
AGTHIA Foods and beverages manufacturer	UAE	0.6
ALICORP Consumer products manufacturer	Peru	0.7
ARIAKE Natural seasonings manufacturer	Japan	2.3
CLICKS GROUP Drugstores operator	South Africa	0.3
COSMOS PHARMACEUTICAL Drugstores operator	Japan	1.8
EDITA FOOD INDUSTRIES Foods and consumer products retailer	Egypt	0.7
GRUPO HERDEZ Processed foods manufacturer	Mexico	1.0
KERNEL Foods and agricultural products manufacturer	Ukraine	0.8
KWS SAAT Agricultural products producer	Germany	1.6
PIGEON Consumer products manufacturer	Japan	0.3
ROHTO PHARMACEUTICAL Health and consumer products mfr	Japan	0.8
ÜLKER Processed foods manufacturer	Turkey	0.9
ENERGY		
CORE LABORATORIES Oilfield services	US	0.5
DIALOG GROUP BERHAD Petrochemical services	Malaysia	1.1
ROMGAZ Natural gas producer	Romania	0.5
FINANCIALS		
BANK OF GEORGIA Commercial bank	UK	0.6
DISCOVERY HOLDINGS Insurance provider	South Africa	0.3
MAX FINANCIAL Financial services and insurance provider	India	2.0
RATHBONE BROS Wealth manager	UK	0.7
SECURITY BANK Commercial bank	Philippines	0.2
SIAULIU BANKAS Commercial bank	Lithuania	0.1
HEALTH CARE		
ABCAM Life science services	UK	2.3
BML Clinical testing and information services	Japan	0.8
CARL ZEISS MEDITEC Medical technology provider	Germany	1.0
DECHRA Veterinary pharma manufacturer	UK	1.9
EMIS GROUP Health care software developer	UK	1.4
INTEGRATED DIAGNOSTICS Medical laboratory services	Egypt	0.8
NAKANISHI Dental instruments manufacturer	Japan	1.1
SQUARE PHARMACEUTICALS Pharma manufacturer	Bangladesh	0.3
STRATEC Life science products manufacturer	Germany	2.5

SECTOR/COMPANY/DESCRIPTION	COUNTRY	END WT (%)
INDUSTRIALS		
51 JOB INC. Online human resource services	China	0.6
BBA AVIATION Flight support systems and services	UK	0.8
BOSSARD Industrial components supplier	Switzerland	1.1
CLARKSON Shipping services	UK	1.1
DIPLOMA Specialized technical services	UK	1.5
FERREYCORP Industrial equipment distributor	Peru	0.8
HAITIAN Plastic injection-molding machines manufacturer	China	1.1
INTRUM JUSTITIA Credit management services	Sweden	1.0
LISI Industrial components manufacturer	France	0.7
MISUMI GROUP Machinery-parts supplier	Japan	0.5
NIHON M&A CENTER INC. Financial advisory	Japan	1.7
PFEIFFER VACUUM Vacuum pump manufacturer	Germany	1.0
SENIOR Aerospace and auto parts manufacturer	UK	0.6
SENSATA TECHNOLOGIES Industrial sensors manufacturer	US	0.2
SMS Health care employment services	Japan	1.7
TOMRA Industrial sensors manufacturer	Norway	2.0
VAT GROUP Vacuum valve manufacturer	Switzerland	0.9
INFORMATION TECHNOLOGY		
ADVANTECH Industrial PCs manufacturer	Taiwan	0.5
ALTEN Technology consultant and engineer	France	1.9
ASM INTERNATIONAL Semiconductor equipment manufacturer	Netherlands	0.7
ASM PACIFIC TECHNOLOGY Semiconductor eqpt manufacturer	Hong Kong	0.7
BECHTLE IT services and IT products reseller	Germany	3.3
CHIPBOND TECHNOLOGY Electronic chip packager	Taiwan	1.0
CYBERARK Cybersecurity software developer	Israel	1.6
GLOBANT Software developer	Argentina	1.6
INFOMART Restaurant supply chain operator	Japan	1.3
KEYWORDS STUDIOS Video game technical services	UK	1.7
KINAXIS Supply chain software developer	Canada	3.1
LEM HOLDINGS Electrical components manufacturer	Switzerland	1.6
NETWORK INTERNATIONAL Electronic payment services	UK	1.4
REPLY IT consultant	Italy	2.4
SILERGY Electronics chips manufacturer	Taiwan	0.9
SIMCORP Asset management software provider	Denmark	0.8
VAISALA Atmospheric measuring devices manufacturer	Finland	2.0
MATERIALS		
FUCHS PETROLUB Lubricants manufacturer	Germany	2.2
HOAPHAT GROUP Steel producer	Vietnam	2.2
JCU Industrial coating manufacturer	Japan	1.3
SH KELKAR Fragrances and flavors manufacturer	India	0.4
REAL ESTATE		
MABANEE Real estate developer and manager	Kuwait	1.0
UTILITIES		
RUBIS Liquid chemical storage and distribution	France	1.9
CASH		
		3.5

Model Portfolio holdings are supplemental information only and complement the fully compliant International Small Companies Composite GIPS Presentation. The portfolio is actively managed therefore holdings shown may not be current. Portfolio holdings should not be considered recommendations to buy or sell any security. It should not be assumed that investment in the security identified has been or will be profitable. To request a complete list of portfolio holdings for the past year contact Harding Loevner.

2Q20 CONTRIBUTORS TO ABSOLUTE RETURN (%)

LARGEST CONTRIBUTORS	SECTOR	AVG. WT.	CONTRIBUTION
KINAXIS	INFT	2.7	1.79
BECHTLE	INFT	3.2	1.19
HOA PHAT GROUP	MATS	2.1	1.15
GLOBANT	INFT	1.4	0.83
REPLY	INFT	2.4	0.80

2Q20 DETRACTORS FROM ABSOLUTE RETURN (%)

LARGEST DETRACTORS	SECTOR	AVG. WT.	CONTRIBUTION
SH KELKAR	MATS	0.4	-0.13
PICO FAREAST HOLDINGS	COMM	0.3	-0.09
NOKIAN TYRES	DSCR	0.1	-0.08
CLICKS GROUP	STPL	0.3	-0.07
SENIOR	INDU	0.7	-0.06

LAST 12 MOS CONTRIBUTORS TO ABSOLUTE RETURN (%)

LARGEST CONTRIBUTORS	SECTOR	AVG. WT.	CONTRIBUTION
KINAXIS	INFT	1.8	2.02
BECHTLE	INFT	2.6	1.44
SILERGY	INFT	0.7	1.07
STRATEC	HLTH	1.6	1.03
PARADOX INTERACTIVE	COMM	1.4	0.96

LAST 12 MOS DETRACTORS FROM ABSOLUTE RETURN (%)

LARGEST DETRACTORS	SECTOR	AVG. WT.	CONTRIBUTION
SENIOR	INDU	1.4	-1.76
ALTEN	INFT	2.4	-1.04
CORE LABORATORIES	ENER	1.4	-0.90
NAKANISHI	HLTH	1.9	-0.66
SH KELKAR	MATS	0.6	-0.61

COMPLETED PORTFOLIO TRANSACTIONS

POSITIONS ESTABLISHED	COUNTRY	SECTOR
JCU	JAPAN	MATS
NOKIAN TYRES	FINLAND	DSCR
YUUGOV	UK	COMM

POSITIONS SOLD	COUNTRY	SECTOR
ALFALAVAL	SWEDEN	INDU
ANADOLU HAYAT EMEKLILIK	TURKEY	FINA
CHARGEURS	FRANCE	DSCR
DANIELI	ITALY	INDU
DIASORIN	ITALY	HLTH
FINDEX	JAPAN	HLTH
IPSOS	FRANCE	COMM
MONOTARO	JAPAN	INDU
PICO FAREAST HOLDINGS	HONG KONG	COMM

The portfolio is actively managed therefore holdings identified above do not represent all of the securities held in the portfolio and holdings may not be current. It should not be assumed that investment in the securities identified has been or will be profitable. The following information is available upon request: (1) information describing the methodology of the contribution data in the charts above; and (2) a list showing the weight and contribution of all holdings during the quarter and the last 12 months. Past performance does not guarantee future results. In the charts above, "weight" is the average percentage weight of the holding during the period, and "contribution" is the contribution to overall performance over the period. Contributors and detractors exclude cash and securities in the Composite not held in the Model Portfolio. Quarterly data is not annualized. Portfolio attribution and characteristics are supplemental information only and complement the fully compliant International Small Companies Composite GIPS Presentation. Portfolio holdings should not be considered recommendations to buy or sell any security.

INTERNATIONAL SMALL COMPANIES EQUITY COMPOSITE PERFORMANCE (AS OF JUNE 30, 2020)

	HL ISC GROSS (%)	HL ISC NET (%)	ACWIEX-US SMALL CAP ¹ (%)	HL ISC 3-YR STD DEVIATION ² (%)	ACWIEX-US SMALL CAP 3-YR STD DEVIATION ² (%)	INTERNAL DISPERSION ³ (%)	NO. OF ACCOUNTS	COMPOSITE ASSETS (\$M)	FIRM ASSETS (%)
2020 YTD ⁴	-7.96	-8.48	-12.61	18.37	18.68	N.A. ⁵	1	332	0.56
2019	31.30	29.83	22.93	12.36	11.60	N.M. ⁶	1	350	0.54
2018	-16.39	-17.34	-17.89	12.47	12.36	N.M.	1	165	0.33
2017	37.61	36.34	32.12	10.76	11.54	N.M.	3	323	0.60
2016	0.79	-0.22	4.29	10.78	12.15	N.M.	2	154	0.40
2015	5.83	4.63	2.95	10.26	11.32	N.M.	1	95	0.29
2014	-2.12	-3.14	-3.69	12.30	13.13	N.M.	3	157	0.45
2013	28.37	26.92	20.13	16.41	16.65	N.M.	3	166	0.50
2012	25.73	24.31	18.96	19.24	19.96	N.M.	2	119	0.53
2011	-11.90	-12.80	-18.21	23.37	23.89	N.M.	2	84	0.62
2010	25.94	24.40	25.58	28.53	30.38	N.M.	1	18	0.16

¹Benchmark Index; ²Variability of the Composite and the Index returns over the preceding 36-month period, annualized; ³Asset-weighted standard deviation (gross of fees); ⁴The 2020 YTD performance returns and assets shown are preliminary; ⁵N.A.—Internal dispersion less than a 12-month period; ⁶N.M.—Information is not statistically significant due to an insufficient number of portfolios in the Composite for the entire year.

The International Small Companies Equity Composite contains fully discretionary, fee-paying accounts investing primarily in non-US equity and equity-equivalent securities of companies with market capitalizations that fall within the range of the Composite's benchmark index and cash reserves. For comparison purposes, the Composite is measured against the MSCI All Country World ex-US Small Cap Total Return Index (Gross). Returns include the effect of foreign currency exchange rates. The exchange rate source of the benchmark is Reuters. The exchange rate source of the Composite is Bloomberg. Additional information about the benchmark, including the percentage of composite assets invested in countries or regions not included in the benchmark, is available upon request.

The MSCI All Country World ex-US Small Cap Index is a free-float market capitalization index that is designed to measure small cap developed and emerging market equity performance. The Index consists of 48 developed and emerging market countries, and is comprised of companies that fall within a market capitalization range of USD 22-10,470 million (as of June 30, 2020). You cannot invest directly in this Index.

Harding Loevner LP claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. Harding Loevner has been independently verified for the period November 1, 1989 through March 31, 2020.

Verification assesses whether (1) the firm has complied with all composite construction requirements of the GIPS standards on a firm-wide basis and (2) the firm's policy and procedures are designed to calculate and present performance in compliance with GIPS standards. The International Small Companies Equity Composite has been examined for the periods January 1, 2007 through March 31, 2020. The verification and performance examination reports are available upon request.

Harding Loevner LP is an investment adviser registered with the Securities and Exchange Commission. Harding Loevner is an affiliate of Affiliated Managers Group, Inc. (NYSE: AMG), an investment holding company with stakes in a diverse group of boutique firms. The firm maintains a complete list and description of composites, which is available upon request.

Results are based on fully discretionary accounts under management, including those accounts no longer with the firm. Composite performance is presented gross of foreign withholding taxes on dividends, interest income and capital gains. Past performance does not guarantee future results. Policies for valuing portfolios, calculating performance, and preparing compliant presentations are available upon request.

The US dollar is the currency used to express performance. Returns are presented both gross and net of management fees and include the reinvestment of all income. Net returns are calculated using actual fees. Actual returns will be reduced by investment advisory fees and other expenses that may be incurred in the management of the account. The standard fee schedule generally applied to separate International Small Companies accounts is 1.00% annually of the market value up to \$20 million; 0.80% of amounts above \$20 million. Actual investment advisory fees incurred by clients may vary. The annual composite dispersion presented is an asset-weighted standard deviation calculated for the accounts in the composite the entire year.

The International Small Companies Equity Composite was created on December 31, 2006.